Dr. Greenberg was previously Senior Vice President for Translational Medicine at Checkmate Pharmaceuticals, where he helped bring innovative immuno-oncology combinations to the clinic. Prior to Checkmate, Dr. Greenberg was Vice President of Global Research, Oncology, at MedImmune (AstraZeneca), where he spearheaded global research activities for immune-mediated and tumor-targeted therapies, a number of which (targeting PDL1, OX40, CD73) have advanced in the clinic. He previously had served as Senior Director of Research, Oncology, at Pfizer, as a Full Member of the Fred Hutchinson Cancer Research Center in Seattle, and as a tenured Professor at Baylor College of Medicine in Houston.
Dr. Greenberg received a BSc in microbiology and immunology from the University of Toronto and a PhD in microbiology and immunology from the University of British Columbia. He performed postdoctoral research at Baylor College of Medicine in Houston.